In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid

Huiyun Zhang,1 Wenya Hua,1 Siran Lin,1 Yu Zhang,1 Xinchang Chen,1 Shiyong Wang,1 Jiazhen Chen,1 Wenhong Zhang1– 3 1Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Sh...

Full description

Bibliographic Details
Published in:Infection and Drug Resistance
Main Authors: Zhang H, Hua W, Lin S, Zhang Y, Chen X, Wang S, Chen J, Zhang W
Format: Article
Language:English
Published: Dove Medical Press 2022-08-01
Subjects:
Online Access:https://www.dovepress.com/in-vitro-susceptibility-of-nontuberculous-mycobacteria-to-tedizolid-peer-reviewed-fulltext-article-IDR
_version_ 1852666545481711616
author Zhang H
Hua W
Lin S
Zhang Y
Chen X
Wang S
Chen J
Zhang W
author_facet Zhang H
Hua W
Lin S
Zhang Y
Chen X
Wang S
Chen J
Zhang W
author_sort Zhang H
collection DOAJ
container_title Infection and Drug Resistance
description Huiyun Zhang,1 Wenya Hua,1 Siran Lin,1 Yu Zhang,1 Xinchang Chen,1 Shiyong Wang,1 Jiazhen Chen,1 Wenhong Zhang1– 3 1Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 2National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Jiazhen Chen, Department of Infectious Diseases, Huashan Hospital, Fudan University, Rm 524, Building No. 5, No. 12 Middle Wulumuqi Road, Shanghai, 200040, People’s Republic of China, Email jiazhen_chen@163.comObjective: Nontuberculous mycobacteria (NTM) can cause pulmonary and extrapulmonary diseases. Tedizolid (TZD) is a new oxazolidinone with in vitro activity against NTM such as Mycobacterium avium complex (MAC), Mycobacterium fortuitum, and Mycobacterium abscessus complex. The aim of this study was to evaluate the TZD susceptibility profiles of clinical isolates of NTM.Methods: The microdilution method was used to identify the minimum inhibitory concentration (MIC) of TZD and linezolid (LZD) for 133 clinical NTM isolates. Broth microdilution chequerboard assays were used to investigate the synergistic effects of TZD and three antibiotics on two reference isolates and eleven clinical isolates of NTM.Results: The TZD MIC50 and MIC90 for M. abscessus complex were 2 and 4 μg/mL, 16 and > 32 μg/mL for MAC, respectively. TZD exhibited lower MICs than that of LZD for most NTM, which were positively correlated. Due to the high MIC values of TZD against MAC, it is necessary to conduct drug sensitivity tests before TZD administration. TZD-clarithromycin combination had synergistic response on M. abscessus complex in 3 of the 8 isolates, which lasted only 3– 5 days. TZD-cefoxitin had synergistic effect against all five M. fortuitum isolates.Conclusion: Our study demonstrates that TZD had greater in vitro potency than LZD, and synergy studies suggested that TZD may be an important component of multi-drug treatment regimen.Keywords: tedizolid, susceptibility testing, nontuberculous mycobacteria, linezolid, oxazolidinone
format Article
id doaj-art-e2d0d9df45cd4068a2a8fc31fc3e849f
institution Directory of Open Access Journals
issn 1178-6973
language English
publishDate 2022-08-01
publisher Dove Medical Press
record_format Article
spelling doaj-art-e2d0d9df45cd4068a2a8fc31fc3e849f2025-08-19T21:35:00ZengDove Medical PressInfection and Drug Resistance1178-69732022-08-01Volume 154845485277665In vitro Susceptibility of Nontuberculous Mycobacteria to TedizolidZhang HHua WLin SZhang YChen XWang SChen JZhang WHuiyun Zhang,1 Wenya Hua,1 Siran Lin,1 Yu Zhang,1 Xinchang Chen,1 Shiyong Wang,1 Jiazhen Chen,1 Wenhong Zhang1– 3 1Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 2National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Jiazhen Chen, Department of Infectious Diseases, Huashan Hospital, Fudan University, Rm 524, Building No. 5, No. 12 Middle Wulumuqi Road, Shanghai, 200040, People’s Republic of China, Email jiazhen_chen@163.comObjective: Nontuberculous mycobacteria (NTM) can cause pulmonary and extrapulmonary diseases. Tedizolid (TZD) is a new oxazolidinone with in vitro activity against NTM such as Mycobacterium avium complex (MAC), Mycobacterium fortuitum, and Mycobacterium abscessus complex. The aim of this study was to evaluate the TZD susceptibility profiles of clinical isolates of NTM.Methods: The microdilution method was used to identify the minimum inhibitory concentration (MIC) of TZD and linezolid (LZD) for 133 clinical NTM isolates. Broth microdilution chequerboard assays were used to investigate the synergistic effects of TZD and three antibiotics on two reference isolates and eleven clinical isolates of NTM.Results: The TZD MIC50 and MIC90 for M. abscessus complex were 2 and 4 μg/mL, 16 and > 32 μg/mL for MAC, respectively. TZD exhibited lower MICs than that of LZD for most NTM, which were positively correlated. Due to the high MIC values of TZD against MAC, it is necessary to conduct drug sensitivity tests before TZD administration. TZD-clarithromycin combination had synergistic response on M. abscessus complex in 3 of the 8 isolates, which lasted only 3– 5 days. TZD-cefoxitin had synergistic effect against all five M. fortuitum isolates.Conclusion: Our study demonstrates that TZD had greater in vitro potency than LZD, and synergy studies suggested that TZD may be an important component of multi-drug treatment regimen.Keywords: tedizolid, susceptibility testing, nontuberculous mycobacteria, linezolid, oxazolidinonehttps://www.dovepress.com/in-vitro-susceptibility-of-nontuberculous-mycobacteria-to-tedizolid-peer-reviewed-fulltext-article-IDRtedizolidsusceptibility testingnontuberculous mycobacterialinezolidoxazolidinone
spellingShingle Zhang H
Hua W
Lin S
Zhang Y
Chen X
Wang S
Chen J
Zhang W
In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
tedizolid
susceptibility testing
nontuberculous mycobacteria
linezolid
oxazolidinone
title In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
title_full In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
title_fullStr In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
title_full_unstemmed In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
title_short In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
title_sort in vitro susceptibility of nontuberculous mycobacteria to tedizolid
topic tedizolid
susceptibility testing
nontuberculous mycobacteria
linezolid
oxazolidinone
url https://www.dovepress.com/in-vitro-susceptibility-of-nontuberculous-mycobacteria-to-tedizolid-peer-reviewed-fulltext-article-IDR
work_keys_str_mv AT zhangh invitrosusceptibilityofnontuberculousmycobacteriatotedizolid
AT huaw invitrosusceptibilityofnontuberculousmycobacteriatotedizolid
AT lins invitrosusceptibilityofnontuberculousmycobacteriatotedizolid
AT zhangy invitrosusceptibilityofnontuberculousmycobacteriatotedizolid
AT chenx invitrosusceptibilityofnontuberculousmycobacteriatotedizolid
AT wangs invitrosusceptibilityofnontuberculousmycobacteriatotedizolid
AT chenj invitrosusceptibilityofnontuberculousmycobacteriatotedizolid
AT zhangw invitrosusceptibilityofnontuberculousmycobacteriatotedizolid